“On May 1, 2026, the U.S. Food and Drug Administration (FDA) approved vepdegestrant (brand name: Veppanu) to treat estrogen receptor-positive, HER2-negative advanced stage or metastatic breast cancer with an ESR1 mutation that grew after being treated with hormonal therapy.

The approval was based on results from the VERITAC-2 trial, which compared vepdegestrant to Faslodex (chemical name: fulvestrant). The results showed that vepdegestrant was more effective for people with metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation that grew while being treated with hormonal therapy and a CDK4/6 inhibitor. The people in the study who took vepdegestrant lived three months longer without the cancer growing than those who received Faslodex. And more of the cancers responded to vepdegestrant than Faslodex — 19% vs. 4%.

Vepdegestrant is a new type of oral selective estrogen receptor downregulator or degrader (SERD) called a PROTAC (proteolosys-targeting chimera). Like other SERDs, vepdegestrant works by blocking estrogen from attaching to cancer cells in the breast. It also destroys the estrogen receptors on the cancer cells and changes the shape of the receptors so they don’t work as well. Because it is a PROTAC, it breaks down the estrogen receptors in a different way than other SERDs.”

From Breastcancer.org.